This material is restricted to non-profit entities only. All recipients are required to sign and submit the acknowledgment of the Limited Use Label License.

NR-53816 is intended for producing pseudotyped particles/pseudovirions and is not for soluble protein expression.

The severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), Wuhan-Hu-1 (GenBank: NC_045512) spike-pseudotyped lentiviral kit version 2 (NR-53816) is designed to generate pseudotyped lentiviral particles with the spike (S) glycoprotein gene, as well as luciferase (Luc2) and green fluorescent protein (GFP). Version 2 replaces the full-length S glycoprotein with a C-terminally truncated spike, which increases titers of viral particles pseudotyped with SARS-CoV-2 spike glycoprotein. Protocols for the use of these items are published, and updates are available at protocols.io.

NR-53816 consists of the five plasmids listed in Table 1. Descriptions of each component are included below.

Table 1: SARS-CoV-2 Lentiviral Kit

Plasmid Type	Insert	BEI Resources Catalog Number
Viral Entry Protein	S Glycoprotein ΔCter	NR-53742
Lentiviral Backbone	Luc2; ZsGreen	NR-52516
Helper Plasmid	Gag; pol	NR-52517
Helper Plasmid	Tat1b	NR-52518
Helper Plasmid	Rev1b	NR-52519

NR-53742, NR-52516, NR-52517, NR-52518 and NR-52519 contain the beta-lactamase gene, bla, to provide transformant selection through ampicillin resistance in Escherichia coli (E. coli).

The complete plasmid sequences and maps are provided on the BEI Resources webpage. The plasmids were produced in E. coli and extracted.

Each kit contains one vial of each plasmid DNA in 10 mM Tris-HCl, 1 mM EDTA, pH 8.0. The vials should be centrifuged prior to opening. Note: The contents of each vial should be used to replicate the plasmid in E. coli prior to mammalian expression.

Luc2
Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for money or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research. Researchers shall have no right to modify or otherwise create variations of the nucleotide sequence of the luciferase gene except that researchers may: (1) create fused gene sequences provided that the coding sequence of the resulting luciferase gene has no more than four deoxynucleotides missing at the affected terminus compared to the intact luciferase gene sequence, and (2) insert and remove nucleic acid sequences in splicing research predicated on the inactivation or reconstitution of the luminescence of the encoded luciferase. No other use or transfer of this product or derivatives is authorized without the prior express written consent of Promega. In addition, researchers must either: (1) use luminescent assay reagents purchased from Promega for all determinations of luminescence activity of this product and its derivatives; or (2) contact Promega to obtain a license for use of the product and its derivatives. Researchers may transfer derivatives to others for research use provided that at the time of transfer a copy of this label license is given to the recipients and recipients agree to be bound by the terms of this label license. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE PRODUCT. The terms of this label license shall be governed under the laws of the State of Wisconsin, USA. This label license relates to Promega patents and/or patent applications on improvements to the luciferase gene.